A

Agenus
D

AGEN

2.76000
USD
-0.07
(-2.47%)
Market Open
Volume
2,976
EPS
-8
Div Yield
-
P/E
-0
Market Cap
64,696,694
OverviewSignalsIdeasNews
Related Instruments
    C
    CRVS
    -0.41000
    (-8.18%)
    4.60000 USD
    F
    FATE
    -0.09000
    (-5.33%)
    1.60000 USD
    G
    GNFT
    0.00000
    (0.00%)
    3.81000 USD
    O
    ONCY
    -0.00510
    (-0.60%)
    0.84000 USD
    P
    PRTA
    0.110
    (0.72%)
    15.290 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    V
    VYGR
    -0.05000
    (-0.87%)
    5.71000 USD
    More
News

Title: Agenus

Sector: Healthcare
Industry: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).